DZ Bank Reaffirms Neutral Rating for Fresenius Medical Care AG & Co. (NYSE:FMS)

Fresenius Medical Care AG & Co. (NYSE:FMS)‘s stock had its “neutral” rating reiterated by research analysts at DZ Bank in a research report issued to clients and investors on Thursday, Borsen Zeitung reports.

FMS has been the subject of a number of other reports. Commerzbank reiterated a “hold” rating and set a $54.00 target price on shares of Fresenius Medical Care AG & Co. in a research report on Thursday, May 9th. Barclays reiterated a “hold” rating and set a $14.00 target price on shares of MACOM Technology Solutions in a research report on Thursday, June 20th. Zacks Investment Research downgraded First Merchants from a “hold” rating to a “sell” rating in a research report on Monday, July 1st. Finally, Royal Bank of Canada cut their target price on from GBX 3,000 ($39.20) to GBX 2,900 ($37.89) and set an “outperform” rating for the company in a research report on Thursday, June 6th. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $53.05.

NYSE:FMS opened at $39.32 on Thursday. The firm’s fifty day moving average is $38.40. The company has a market cap of $24.30 billion, a P/E ratio of 15.97, a price-to-earnings-growth ratio of 2.81 and a beta of 1.43. The company has a current ratio of 1.02, a quick ratio of 0.79 and a debt-to-equity ratio of 0.73. Fresenius Medical Care AG & Co. has a fifty-two week low of $30.99 and a fifty-two week high of $53.40.

Fresenius Medical Care AG & Co. (NYSE:FMS) last released its earnings results on Thursday, May 2nd. The company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.52 by $0.07. The firm had revenue of $4.13 billion during the quarter, compared to the consensus estimate of $4.58 billion. Fresenius Medical Care AG & Co. had a return on equity of 10.27% and a net margin of 11.94%. The company’s revenue was up 3.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.91 EPS. On average, analysts expect that Fresenius Medical Care AG & Co. will post 2.4 EPS for the current fiscal year.

Hedge funds have recently made changes to their positions in the stock. Two Sigma Investments LP bought a new stake in shares of Fresenius Medical Care AG & Co. during the 4th quarter worth $7,553,000. Renaissance Group LLC lifted its position in shares of Fresenius Medical Care AG & Co. by 33.3% during the 1st quarter. Renaissance Group LLC now owns 377,246 shares of the company’s stock worth $15,290,000 after buying an additional 94,236 shares during the last quarter. Stifel Financial Corp lifted its position in shares of Fresenius Medical Care AG & Co. by 49.9% during the 4th quarter. Stifel Financial Corp now owns 20,179 shares of the company’s stock worth $659,000 after buying an additional 6,720 shares during the last quarter. Duff & Phelps Investment Management Co. bought a new stake in shares of Fresenius Medical Care AG & Co. during the 1st quarter worth $3,677,000. Finally, Deutsche Bank AG lifted its position in shares of Fresenius Medical Care AG & Co. by 1,658.2% during the 4th quarter. Deutsche Bank AG now owns 330,544 shares of the company’s stock worth $10,705,000 after buying an additional 311,744 shares during the last quarter. Institutional investors and hedge funds own 1.45% of the company’s stock.

Fresenius Medical Care AG & Co. Company Profile

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Featured Story: Should You Consider an Index Fund?

Analyst Recommendations for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.